FDA approves monthly maintenance dosing for Biogen/Eisai's Alzheimer's drug, Leqembi, showing positive growth in treatment options.

From Investing.com: 2025-01-26 19:05:14

The FDA approved monthly maintenance dosing for Eisai and Biogen’s Alzheimer’s drug, Leqembi, following 18 months of biweekly infusions. The drug slows cognitive decline and targets amyloid beta protein deposits in the brain. In 2023, Leqembi received standard FDA approval, competing with Eli Lilly’s monthly-administered Kisunla for Alzheimer’s treatment.



Read more at Investing.com: US FDA approves monthly maintenance dosing for Biogen/Eisai Alzheimer’s drug By Investing.com